Abstract
The use of Surface Plasmon Resonance (SPR)-based optical biosensors contributes extensively to discovery and development of therapeutic monoclonal antibodies, owing to its ability to real-time analyze interactions of an antigen with an antibody without intrinsic or extrinsic labels. SPR has been a mainstay in pharmaceutical companies for almost two decades, and its role in drug discovery has experienced significant growth with the expanded number of therapeutic antibodies. Additionally, the burgeoning field of biosimilars depends on SPR to ascertain comparability to innovator mAbs. While the promise of the technology is exciting, the full role of SPR has yet to be realized. SPR has historically been hampered by limited throughput; however, new instruments and methods have emerged that allow for the analysis of up to thousands of biomolecular interactions per day. Here, we detail the use of traditional and emerging SPR techniques for characterizing monoclonal antibodies such as antigen/antibody kinetics, epitope profiling, and immunogenicity screening. In conjunction with efforts to improve throughput and sensitivity, SPR is expected to continue in its growth as a central technique in pharmaceutical discovery and development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Boozer C, Kim G, Cong S et al (2006) Looking towards label-free biomolecular interaction analysis in a high-throughput format: a review of new surface plasmon resonance technologies. Curr Opin Biotechnol 17:400–405. doi:10.1016/j.copbio.2006.06.012
Evans JB, Syed BA (2014) From the analyst’s couch: next-generation antibodies. Nat Rev Drug Discov 13(6):413–414
Epstein MS, Ehrenpreis ED, Kulkarni PM (2014) Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol 109:1856–1859. doi:10.1038/ajg.2014.151
Sitte HH, Freissmuth M (2013) Biosimilars versus generics: scientific basics and clinical implications. Mag Eur Med Oncol 6(3):202–206
Walsh G (2014) Biopharmaceutical benchmarks. Nat Biotechnol 32:992–1000. doi:10.1038/nbt.3040
Arnum PV (2013) Tracking growth in biologics. Pharm Technol 37:16
Rich RL, Myszka DG (2004) Why you should be using more SPR biosensor technology. Drug Discov Today Technol 1:301–308
Myszka DG, Rich RL (2003) SPR’s high impact on drug discovery: resolution, throughput and versatility. Drug Discov World 49(1):49–55
Homola J, Yee SS, Gauglitz G (1999) Surface plasmon resonance sensors: review. Sens Actuators B Chem 54:3–15. doi:10.1016/S0925-4005(98)00321-9
Homola J, Piliarik M (2006) Surface plasmon resonance (SPR) sensors. In: Surface plasmon resonance sensors. Springer, p 45–67
Weingart CL, Broitman-Maduro G, Dean G et al (1999) Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 67:4264–4267
Altschuh D, Dubs MC, Weiss E, Zeder-Lutz G, Van Regenmortel MHV (1992) Determination of kinetic constants for the interaction between a monoclonal antibody and peptides using surface plasmon resonance. Biochemistry 31(27):6298–6304
Wammes AEM, Fischer MJE, de Mol NJ et al (2013) Site-specific peptide and protein immobilization on surface plasmon resonance chips via strain-promoted cycloaddition. Lab Chip 13:1863–1867. doi:10.1039/c3lc41338a
Kooyman RPH, Corn RM, Frazier RA et al (2008) Handbook of surface plasmon resonance: RSC, 1st edn. Royal Society of Chemistry, Cambridge, UK
Rich RL, Myszka DG (2008) Survey of the year 2007 commercial optical biosensor literature. J Mol Recognit 21:355–400
Haab BB, Dunham MJ, Brown PO (2001) Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2(2)
MacBeath G, Schreiber SL (2000) Printing proteins as microarrays for high-throughput function determination. Science 289:1760–1763
Houseman BT, Mrksich M (2002) Towards quantitative assays with peptide chips: a surface engineering approach. Trends Biotechnol 20:279–281. doi:10.1016/S0167-7799(02)01984-4
Vijayendran RA, Leckband DE (2001) A quantitative assessment of heterogeneity for surface-immobilized proteins. Anal Chem 73:471–480. doi:10.1021/ac000523p
Firestone MA, Shank ML, Sligar SG, Bohn PW (1996) Film architecture in biomolecular assemblies. Effect of linker on the orientation of genetically engineered surface-bound proteins. J Am Chem Soc 118:9033–9041. doi:10.1021/ja961046o
Canziani GA, Klakamp S, Myszka DG (2004) Kinetic screening of antibodies from crude hybridoma samples using Biacore. Anal Biochem 325:301–307. doi:10.1016/j.ab.2003.11.004
Natarajan S, Katsamba PS, Miles A et al (2008) Continuous-flow microfluidic printing of proteins for array-based applications including surface plasmon resonance imaging. Anal Biochem 373:141–146. doi:10.1016/j.ab.2007.07.035
Leckband D (2000) Measuring the forces that control protein interactions. Annu Rev Biophys Biomol Struct 29:1–26. doi:10.1146/annurev.biophys.29.1.1
Holmberg A, Blomstergren A, Nord O, Lukacs M, Lundeberg J, Uhlén M (2005) The biotin-streptavidin interaction can be reversibly broken using water at elevated temperatures. Electrophoresis 26(3):501–510
Schuck P, Zhao H (2010) The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol Biol 627:15–54. doi:10.1007/978-1-60761-670-2_2
Drake AW, Myszka DG, Klakamp SL (2004) Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem 328:35–43. doi:10.1016/j.ab.2003.12.025
Myszka DG (1997) Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotechnol 8:50–57
Karlsson R, Michaelsson A, Mattsson L (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145:229–240. doi:10.1016/0022-1759(91)90331-9
Christensen LLH (1997) Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 249:153–164. doi:10.1006/abio.1997.2182
Van Regenmortel MH, Altschuh D, Chatellier J et al (1998) Measurement of antigen-antibody interactions with biosensors. J Mol Recognit 11:163–167
Myszka DG, He X, Dembo M et al (1998) Extending the range of rate constants available from BIACORE: interpreting mass transport-influenced binding data. Biophys J 75:583–594
Myszka DG (1999) Improving biosensor analysis. J Mol Recognit 12:279–284
Drake AW, Papalia GA (2012) Biophysical considerations for development of antibody-based therapeutics. In: Bornstein GG, Klakamp SL, Tabrizi MA (eds) Developments in antibody-based therapies. Springer, New York, NY, pp 95–139
Wijaya E, Lenaerts C, Maricot S et al (2011) Surface plasmon resonance-based biosensors: from the development of different SPR structures to novel surface functionalization strategies. Curr Opin Solid State Mater Sci 15:208–224. doi:10.1016/j.cossms.2011.05.001
Buenger D, Topuz F, Groll J (2012) Hydrogels in sensing applications. Prog Polym Sci 37:1678–1719. doi:10.1016/j.progpolymsci.2012.09.001
Van Der Merwe PA (2001) Surface plasmon resonance. Oxford University Press, New York, NY
Andersson DI, Hughes D (2012) Evolution of antibiotic resistance at non-lethal drug concentrations. Drug Resist Updat 15:162–172. doi:10.1016/j.drup.2012.03.005
Murphy M, Jason-Moller L, Bruno J (2001) Using Biacore to measure the binding kinetics of an antibody-antigen interaction. Curr Protoc Protein Sci. Chapter 19:Unit 19.14. doi: 10.1002/0471142301.ps1914s45
Drake AW, Klakamp SL (2011) A strategic and systematic approach for the determination of biosensor regeneration conditions. J Immunol Methods 371:165–169. doi:10.1016/j.jim.2011.06.003
Rich RL, Myszka DG (2000) Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol 11:54–61
Karlsson R, Fält A (1997) Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods 200:121–133. doi:10.1016/S0022-1759(96)00195-0
Katsamba PS, Navratilova I, Calderon-Cacia M et al (2006) Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal Biochem 352:208–221. doi:10.1016/j.ab.2006.01.034
Papalia GA, Baer M, Luehrsen K et al (2006) High-resolution characterization of antibody fragment/antigen interactions using Biacore T100. Anal Biochem 359:112–119. doi:10.1016/j.ab.2006.08.032
Säfsten P, Klakamp SL, Drake AW et al (2006) Screening antibody–antigen interactions in parallel using Biacore A100. Anal Biochem 353:181–190. doi:10.1016/j.ab.2006.01.041
Jason-Moller L, Murphy M, Bruno J (2006) Overview of Biacore systems and their applications. Curr Protoc Protein Sci. Chapter 19: Unit 19.13.doi:10.1002/0471140864.ps1913s45
Morton TA, Myszka DG, Chaiken IM (1995) Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. Anal Biochem 227:176–185. doi:10.1006/abio.1995.1268
Mol NJ, Fischer MJE (2010) Surface plasmon resonance: a general introduction. In: Fischer MJE, Mol NJ (eds) Surface plasmon resonance. Humana, New York, NY, pp 1–14
O’Shannessy DJ (1994) Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: a critique of the surface plasmon resonance literature. Curr Opin Biotechnol 5:65–71. doi:10.1016/S0958-1669(05)80072-2
Cheskis B, Freedman LP (1996) Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance. Biochemistry (Mosc) 35:3309–3318. doi:10.1021/bi952283r
Heding A, Gill R, Ogawa Y et al (1996) Biosensor measurement of the binding of insulin-like growth factors i and ii and their analogues to the insulin-like growth factor-binding protein-3. J Biol Chem 271:13948–13952. doi:10.1074/jbc.271.24.13948
Persson E, Ezban M, Shymko RM (1995) Kinetics of the interaction between the human factor VIIIa subunits: effects of pH, ionic strength, Ca2+ concentration, heparin, and activated protein C-catalyzed proteolysis. Biochemistry (Mosc) 34:12775–12781. doi:10.1021/bi00039a038
Gertler A, Grosclaude J, Strasburger CJ et al (1996) Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. J Biol Chem 271:24482–24491. doi:10.1074/jbc.271.40.24482
Masson L, Lu Y, Mazza A et al (1995) The CryIA(c) receptor purified from Manduca sexta displays multiple specificities. J Biol Chem 270:20309–20315. doi:10.1074/jbc.270.35.20309
Edlund M, Blikstad I, Öbrink B (1996) Calmodulin binds to specific sequences in the cytoplasmic domain of c-cam and down-regulates c-cam self-association. J Biol Chem 271:1393–1399. doi:10.1074/jbc.271.3.1393
Raghavan M, Wang Y, Bjorkman PJ (1995) Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci U S A 92:11200–11204
Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (Mosc) 34:14649–14657
Sasaki T, Göhring W, Pan T et al (1995) Binding of mouse and human fibulin-2 to extracellular matrix ligands. J Mol Biol 254:892–899. doi:10.1006/jmbi.1995.0664
Sundberg F (2009) Kinetics from SPR. Drug Discov Dev 12(2):22–24
Myszka DG, Morton TA, Doyle ML, Chaiken IM (1997) Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor. Biophys Chem 64:127–137. doi:10.1016/S0301-4622(96)02230-2
Keighley W (2011) The need for high throughput kinetics early in the drug discovery process. Drug Discov World 12:39–45
Brooks BD (2014) The importance of epitope binning for biological drug discovery. Curr Drug Discov Technol 11(2):109–112
Brooks BD, Miles A, Abdiche Y (2014) High-throughput epitope binning of therapeutic monoclonal antibodies: why you need to bin the fridge. Drug Discov Today 19(8):1040–1044. doi:10.1016/j.drudis.2014.05.011
Abdiche Y, Malashock D, Pinkerton A, Pons J (2008) Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 377:209–217. doi:10.1016/j.ab.2008.03.035
Abdiche YN, Lindquist KC, Stone DM et al (2012) Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity. J Immunol Methods 382:101–116. doi:10.1016/j.jim.2012.05.010
Abdiche YN, Malashock DS, Pinkerton A, Pons J (2009) Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. Anal Biochem 386:172–180. doi:10.1016/j.ab.2008.11.038
Brooks BD, Albertson AE, Jones JA et al (2008) Efficient screening of high-signal and low-background antibody pairs in the bio-bar code assay using prion protein as the target. Anal Biochem 382:60–62. doi:10.1016/j.ab.2008.07.009
Miller PL, Wolfert RL, Diedrich G (2011) Epitope binning of murine monoclonal antibodies by a multiplexed pairing assay. J Immunol Methods 365:118–125. doi:10.1016/j.jim.2010.12.021
Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668. doi:10.1002/jps.20178
Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317:1261–1269. doi:10.1016/j.yexcr.2011.02.013
Luzzago A, Felici F, Tramontano A et al (1993) Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 128:51–57. doi:10.1016/0378-1119(93)90152-S
Stephen CW, Lane DP (1992) Mutant conformation of p53: precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225:577–583. doi:10.1016/0022-2836(92)90386-X
Zuiderweg ERP (2002) Mapping protein–protein interactions in solution by NMR spectroscopy†. Biochemistry (Mosc) 41:1–7. doi:10.1021/bi011870b
Marciano DP, Dharmarajan V, Griffin PR (2014) HDX-MS guided drug discovery: small molecules and biopharmaceuticals. Curr Opin Struct Biol 28:105–111. doi:10.1016/j.sbi.2014.08.007
Mihai S, Nimmerjahn F (2013) The role of Fc receptors and complement in autoimmunity. Autoimmun Rev 12:657–660. doi:10.1016/j.autrev.2012.10.008
Rosales C, Uribe-Querol E (2013) Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol 4:21
Mellor JD, Brown MP, Irving HR et al (2013) A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:8722–8726
Clynes R (2006) Antitumor antibodies in the treatment of cancer: fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 20:585–612. doi:10.1016/j.hoc.2006.02.010
Nimmerjahn F, Ravetch JV (2012) Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12:13
Lazar GA, Dang W, Karki S et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005–4010. doi:10.1073/pnas.0508123103
Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:685–691
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725
Ober RJ, Radu CG, Ghetie V, Ward ES (2001) Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551–1559
Chen Y, Balthasar JP (2012) Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 14:850–859
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357. doi:10.1038/nri1837
Patel R, Johnson KK, Andrien BA, Tamburini PP (2013) IGg subclass variation of a monoclonal antibody binding to human fc-gamma receptors. Am J Biochem Biotechnol 9:206
Li P, Jiang N, Nagarajan S et al (2007) Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands. J Biol Chem 282:6210–6221. doi:10.1074/jbc.M609064200
Bruhns P, Iannascoli B, England P et al (2009) Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725
Kiese S, Papppenberger A, Friess W, Mahler H-C (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347–4366. doi:10.1002/jps.21328
Fincke A, Winter J, Bunte T, Olbrich C (2014) Thermally induced degradation pathways of three different antibody-based drug development candidates. Eur J Pharm Sci 62:148–160. doi:10.1016/j.ejps.2014.05.014
Bhatnagar BS, Bogner RH, Pikal MJ (2007) Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12:505–523
Haberger M, Bomans K, Diepold K, et al. (2014) Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. mAbs. Landes Bioscience, p 327
Chumsae C, Gaza-Bulseco G, Sun J, Liu H (2007) Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B 850:285–294
Rich RL, Miles AR, Gale BK, Myszka DG (2009) Detergent screening of a G-protein-coupled receptor using serial and array biosensor technologies. Anal Biochem 386:98–104. doi:10.1016/j.ab.2008.12.011
Locatelli-Hoops S, Yeliseev AA, Gawrisch K, Gorshkova I (2013) Surface plasmon resonance applied to G protein-coupled receptors. Biomed Spectrosc Imaging 2:155–181. doi:10.3233/BSI-130045
Stenlund P, Babcock GJ, Sodroski J, Myszka DG (2003) Capture and reconstitution of G protein-coupled receptors on a biosensor surface. Anal Biochem 316:243–250
Parrill AL (2008) Crystal structures of a second g protein-coupled receptor: triumphs and implications. ChemMedChem 3:1021–1023. doi:10.1002/cmdc.200800070
Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996. doi:10.1038/nrd2199
Hutchings CJ, Koglin M, Marshall FH (2010) Therapeutic antibodies directed at G protein-coupled receptors. mAbs 2:594–606. doi:10.4161/mabs.2.6.13420
Karlsson OP, Löfås S (2002) Flow-mediated on-surface reconstitution of g-protein coupled receptors for applications in surface plasmon resonance biosensors. Anal Biochem 300:132–138. doi:10.1006/abio.2001.5428
Hodnik V, Anderluh G (2010) Capture of intact liposomes on biacore sensor chips for protein–membrane interaction studies. In: Fischer MJE, Mol NJ (eds) Surface plasmon reson. Humana, New York, NY, pp 201–211
Cooper MA (2002) Optical biosensors in drug discovery. Nat Rev Drug Discov 1:515–528
Cooper MA, Hansson A, Löfås S, Williams DH (2000) A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal Biochem 277:196–205. doi:10.1006/abio.1999.4389
Johnsson B, Löfås S, Lindquist G (1991) Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 198:268–277. doi:10.1016/0003-2697(91)90424-R
Navratilova I, Dioszegi M, Myszka DG (2006) Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Anal Biochem 355:132–139
Mirzabekov T, Kontos H, Farzan M et al (2000) Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 18:649–654. doi:10.1038/76501
Babcock GJ, Mirzabekov T, Wojtowicz W, Sodroski J (2001) ligand binding characteristics of cxcr4 incorporated into paramagnetic proteoliposomes. J Biol Chem 276:38433–38440. doi:10.1074/jbc.M106229200
Chen L, Jin L, Zhou N (2012) An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov 7:791–806. doi:10.1517/17460441.2012.699036
Harding PJ, Hadingham TC, McDonnell JM, Watts A (2006) Direct analysis of a GPCR-agonist interaction by surface plasmon resonance. Eur Biophys J 35:709–712. doi:10.1007/s00249-006-0070-x
Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3–10
Wright A, Shin S-U, Morrison SL (1991) Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12:125–168
De Groot AS et al (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620–626. doi:10.1016/j.coph.2008.08.002
Harding FA, Stickler MM, Razo J, Du Bridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs 2:256–265
Cheung NK, Guo H, Hu J et al (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 1:477–486
Kaliyaperumal A, Pennucci J, Nagatani J et al (2014) A method to quantitate the neutralizing capacity of anti-therapeutic protein antibodies in serum and their correlation to clinical impact. J Pharm Biomed Anal 102C:176–183. doi:10.1016/j.jpba.2014.09.009
Mikulskis A, Yeung D, Subramanyam M, Amaravadi L (2011) Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J Immunol Methods 365:38–49
Nechansky A (2010) HAHA–nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J Pharm Biomed Anal 51:252–254
Barbosa MD, Gokemeijer J, Martin AD, Bush A (2013) Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies. Anal Biochem 441:174–179
Lofgren JA, Dhandapani S, Pennucci JJ et al (2007) Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 178:7467–7472
Weeraratne DK, Lofgren J, Dinnogen S et al (2013) Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 396:44–55
Elvin JG, Couston RG, van der Walle CF (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 440:83–98. doi:10.1016/j.ijpharm.2011.12.039
Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136. doi:10.1038/nbt1142
Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352. doi:10.1038/nri2747
Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27:331–337
Steukers M, Schaus J-M, van Gool R et al (2006) Rapid kinetic-based screening of human Fab fragments. J Immunol Methods 310:126–135. doi:10.1016/j.jim.2006.01.002
Wassaf D, Kuang G, Kopacz K et al (2006) High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. Anal Biochem 351:241–253. doi:10.1016/j.ab.2006.01.043
Hoogenboom HR, de Bruïne AP, Hufton SE et al (1998) Antibody phage display technology and its applications. Immunotechnology 4:1–20. doi:10.1016/S1380-2933(98)00007-4
Kehoe JW, Kay BK (2005) Filamentous phage display in the new millennium. Chem Rev 105:4056–4072. doi:10.1021/cr000261r
Azzazy HME, Highsmith WE Jr (2002) Phage display technology: clinical applications and recent innovations. Clin Biochem 35:425–445. doi:10.1016/S0009-9120(02)00343-0
Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105–1116. doi:10.1038/nbt1126
Mondon P (2008) Human antibody libraries: a race to engineer and explore a larger diversity. Front Biosci 13:1117. doi:10.2741/2749
Conroy PJ, Hearty S, Leonard P, O’Kennedy RJ (2009) Antibody production, design and use for biosensor-based applications. Semin Cell Dev Biol 20:10–26. doi:10.1016/j.semcdb.2009.01.010
Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29–49
Leonard P, Säfsten P, Hearty S et al (2007) High throughput ranking of recombinant avian scFv antibody fragments from crude lysates using the Biacore A100. J Immunol Methods 323:172–179. doi:10.1016/j.jim.2007.04.010
Bravman T, Bronner V, Lavie K et al (2006) Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 358:281–288. doi:10.1016/j.ab.2006.08.005
Rich RL, Quinn JG, Morton T et al (2010) Biosensor-based fragment screening using FastStep injections. Anal Biochem 407:270–277
Shepherd CA, Hopkins AL, Navratilova I (2014) Fragment screening by SPR and advanced application to GPCRs. Prog Biophys Mol Biol 116:113–123. doi:10.1016/j.pbiomolbio.2014.09.008, pii: S0079-6107(14)00110-2
Chardin H et al (2014) Surface Plasmon Resonance imaging: a method to measure the affinity of the antibodies in allergy diagnosis. J Immunol Methods 405:23–28. doi:10.1016/j.jim.2013.12.010
Schasfoort R, de Lau W, van der Kooi A et al (2012) Method for estimating the single molecular affinity. Anal Biochem 421:794–796
Liu S, Zhu JH, He LP et al (2014) Label-free, real-time detection of the dynamic processes of protein degradation using oblique-incidence reflectivity difference method. Appl Phys Lett 104:163701. doi:10.1063/1.4873676
Wöllner K, Chen X, Kremmer E, Krämer PM (2010) Comparative surface plasmon resonance and enzyme-linked immunosorbent assay characterisation of a monoclonal antibody with N-acyl homoserine lactones. Anal Chim Acta 683:113–118. doi:10.1016/j.aca.2010.10.015
Thorpe R, Swanson SJ (2005) Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 20:16–22. doi:10.1093/ndt/gfh1086
Heinrich L, Tissot N, Hartmann DJ, Cohen R (2010) Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol Methods 352:13–22. doi:10.1016/j.jim.2009.10.002
Tacey R, Greway A, Smiell J et al (2003) The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods 283:317–329
Jecklin MC, Schauer S, Dumelin CE, Zenobi R (2009) Label-free determination of protein-ligand binding constants using mass spectrometry and validation using surface plasmon resonance and isothermal titration calorimetry. J Mol Recognit 22:319–329. doi:10.1002/jmr.951
Azzam RMA, Rigby PG, Krueger JA (1977) Kinetics of protein adsorption and immunological reactions at a liquid/solid interface by ellipsometry. Phys Med Biol 22:422. doi:10.1088/0031-9155/22/3/002
Ndieyira JW, Watari M, Barrera AD et al (2008) Nanomechanical detection of antibiotic-mucopeptide binding in a model for superbug drug resistance. Nat Nanotechnol 3:691–696. doi:10.1038/nnano.2008.275
Ciambrone GJ, Liu VF, Lin DC et al (2004) Cellular dielectric spectroscopy: a powerful new approach to label-free cellular analysis. J Biomol Screen 9:467–480. doi:10.1177/1087057104267788
Peters MF, Vaillancourt F, Heroux M et al (2010) Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol 8:219–227. doi:10.1089/adt.2009.0232
Chua JH, Chee R-E, Agarwal A et al (2009) Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays. Anal Chem 81:6266–6271. doi:10.1021/ac901157x
Navratilova I (2005) Measuring long association phases using Biacore. Anal Biochem 344:295–297. doi:10.1016/j.ab.2005.05.025
Abdiche YN, Malashock DS, Pons J (2008) Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 17:1326–1335. doi:10.1110/ps.035402.108
Mayer KM, Hafner JH (2011) Localized surface plasmon resonance sensors. Chem Rev 111:3828–3857. doi:10.1021/cr100313v
Sun Y-S, Landry JP, Fei Y, Zhu X (2013) An oblique-incidence reflectivity difference study of the dependence of probe-target reaction constants on surface target density using streptavidin-biotin reactions as a model. Instrum Sci Technol 41:535–544. doi:10.1080/10739149.2013.775590
Concepcion J, Witte K, Wartchow C et al (2009) Label-free detection of biomolecular interactions using biolayer interferometry for kinetic characterization. Comb Chem High Throughput Screen 12:791–800
Chiu Y-W, Li QX, Karu AE (2001) Selective binding of polychlorinated biphenyl congeners by a monoclonal antibody: analysis by kinetic exclusion fluorescence immunoassay. Anal Chem 73:5477–5484. doi:10.1021/ac0102462
Murphy KP, Freire E, Paterson Y (1995) Configurational effects in antibody–antigen interactions studied by microcalorimetry. Proteins Struct Funct Bioinforma 21:83–90. doi:10.1002/prot.340210202
Leder L, Berger C, Bornhauser S et al (1995) Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide-antibody recognition. Biochemistry (Mosc) 34:16509–16518
Kreimann M, Brandt S, Krauel K et al (2014) Interaction between platelet factor 4 and heparins: thermodynamics determines conformational changes required for binding of anti-platelet factor 4/heparin antibodies. Blood. doi: 10.1182/blood-2014-03-559518
Ciulli A (2013) Biophysical screening for the discovery of small-molecule ligands. Methods Mol Biol 1008:357–388. doi:10.1007/978-1-62703-398-5_13
Gell DA, Grant RP, Mackay JP (2012) The detection and quantitation of protein oligomerization. Adv Exp Med Biol 747:19–41. doi:10.1007/978-1-4614-3229-6_2
Fleming MR, Shamah SM, Kaczmarek LK (2014) Use of label-free optical biosensors to detect modulation of potassium channels by G-protein coupled receptors. J Vis Exp 84:e51307. doi:10.3791/51307
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Davidoff, S.N., Ditto, N.T., Brooks, A.E., Eckman, J., Brooks, B.D. (2015). Surface Plasmon Resonance for Therapeutic Antibody Characterization. In: Fang, Y. (eds) Label-Free Biosensor Methods in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2617-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2617-6_3
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2616-9
Online ISBN: 978-1-4939-2617-6
eBook Packages: Springer Protocols